Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up

Annals of Oncology

Volumn 7, Issue 4, 1996, Pages 365-371

  Lassen, U ^a   Kristjansen, P E G ^a   Osterlind K ^d   Bergman, B ^e   Sigsgaard, T C ^b   Hirsch, F R ^c   Hansen, M ^d   Dombernowsky, P ^b   Hansen, H H ^a  

^a FINSEN LABORATORY   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

^d HILLERØD HOSPITAL   (Denmark)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Carboplatin; Cisplatin; Platinuminduction; Small cell lung cancer

Indexed keywords

ALTRETAMINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; LOMUSTINE; TENIPOSIDE; VINCRISTINE; VINDESINE;

ADULT; AGED; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTICEMIA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0030037201     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010603     Document Type: Article

References (31)

1. Hansen HH. Management of small cell lung cancer. Lancet 1992; 339: 846-9.
2. Lassen U, Østerlind K. Hansen M et al. Long-term survival in small cell lung cancer: Posttreatment characteristics in patients surviving 5 to 18+ years - an analysis of 1,714 consecutive patients. J Clin Oncol 1995; 13: 1215-20.
3. Elliott JA, Østerlind K, Hansen HH. Cyclic alternating 'non-cross resistant' chemotherapy in the management of small cell anaplastic carcinoma of the lung. Cancer Treat Rev 1984; 11: 103-13.
4. Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727-33.
5. Østerlind K, Sorenson S, Hansen HH et al. Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung. Cancer Res 1983; 43: 6085-9.
6. Daniels JR, Chak LY, Sikic BI et al. Chemotherapy of small cell carcinoma of the lung: Randomized comparison of alternating and sequential combination chemotherapy programs. J Clin Oncol 1984; 2: 1192.
7. Østerlind K. Alternating or sequential chemotherapy in small cell lung cancer? Lung Cancer 1989; 5: 173-7.
8. Pedersen A, Bork E, Østerlind K et al. Phase II study of teniposide in small cell carcinoma of the lung. Cancer Treat Rep 1984; 68: 1289-91.
9. Bork E, Hansen M, Dombernowsky P et al. Teniposide (VM-26). An overlooked highly active agent in small cell lung cancer. Results of a phase II trial in untreated patients. J Clin Oncol 1986; 4: 524-8.
10. Mabel JA. Therapeutic synergism in murin tumors for combinations of cisdiammine-dichlor-platimim with VP-16 or BCNU. Proc Am Ass Cancer Res 1981; 20: 230.
11. Pedersen A, Hansen HH. Etoposide (VP-16) in the treatment of lung cancer. Cancer Treat Rev 1983; 10: 245-64.
12. Smith IE, Harland SJ, Robinson BA et al. Carboplatin: A very active new cisplatin analog in the treatment of small cell lung cancer. Cancer Treat Rep 1985; 69: 43-6.
13. Smith IE, Evans BD, Gore ME et al. Carboplatin (JM-8) and etoposide (VP-16) as first-line combination chemotherapy for small cell lung carcinoma. J Clin Oncol 1987; 5: 185-9.
14. Bork E, Ersbøll J, Dombernowsky P et al. Teniposide and etoposide in previously untreated small-cell lung cancer: A randomized study. J Clin Oncol 1991; 9: 1627-31.
15. Østerlind K, Hansen HH, Hansen HS et al. Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer: Results of a controlled trial with 5 years follow-up. Br J Cancer 1986; 54: 7-17.
16. BMDP Statistical Software. Berkeley, University of California.
17. Cox DR. Analysis of Binary Data. London: British Medical Association 1980.
18. Evans WK, Feld R, Murray N et al. Superiority of alternating non-cross resistant chemotherapy in extensive small cell lung cancer. Ann Intern Med 1987; 107: 451-547.
19. Feld R, Evans WK, Coy P et al. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross resistant chemotherapy combinations in patients with limited small cell carcinoma of the lung. J Clin Oncol 1987; 5: 1401-9.
20. Roth BJ, Johnson DH, Einhorn LH et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the South-eastern Cancer Study Group. J Clin Oncol 1992; 10: 282-91.
21. Souhami RL, Law K. Longevity in small cell lung cancer: A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. Br J Cancer 1990; 61: 584-9.
22. Rosti G, Donadio M, Crino L. Long survivors in small cell lung cancer (SCLC): Italian report on 3,245 cases. Proc Am Soc Clin Oncol 1991; 10: 268.
23. Gatzemeier U, Hossfeld DK, Neuhauss R et al. Phase II and III studies with carboplatin in small cell lung cancer. Semin Oncol 1992; 19(Suppl 2): 28-36.
24. Wolf M, Havemann K, Drings P et al. Phase III study of an alternating chemotherapy with adriamycin/ifosfamide/vincristin and cisplatin/etoposide or carboplatin/etoposide in small cell lung cancer. Proc Am Soc Clin Oncol 1989; 8: 236.
25. Pignon JP, Arriagada R, Inde DC et al. A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 1992; 327: 1618-24.
26. Bunn P. Review of therapeutic trials of carboplatin in lung cancer. Semin Oncol 1989; 16 (Suppl 2): 27-33.
27. Bunn P, Cullen M, Fukuoka M. Chemotherapy in small cell lung cancer: A consensus report. Lung Cancer 1989; 5: 127-34.
28. Bleehen NM, Fayers PM, Girling DJ et al. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small cell lung cancer. Br J Cancer 1989; 59: 584-90.
29. Ettinger DS, Finkelstein DM, Sarma R et al. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 1995; 13: 1431-5.
30. Ardizzoni A, Hansen H, Dombernowsky P et al. Phase II study of topetecan in pretreated small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 1994; 13: 336
31. Cormier Y, Eisenhauer EA, Muldal A et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). Ann Oncol 1994; 5: 283-5.